The robustness and specificity of the LC method were established. Changes in the chromatographic system (column, mobile phase, pH, wavelength, and temperature) were used to evaluate the robustness. The retention time observed allowed a rapid determination of the drug, which is important for routine analysis. The use of mobile phase with out buffer which lengthen the column life is the main advantage for the proposed LC method. No interferences from excipients present in pharmaceutical formulation was observed at the detection wavelength. The chromatographic peak of analyte was not attributable to more than one component. At the same concentration, the peak areas of voriconazole standard and sample solutions were identical.

All these factors lead to the conclusion that the proposed method is accurate, precise, simple, sensitive, selective, robust and rapid and can be applied successfully for the estimation of voriconazole in bulk and in pharmaceutical formulations.

REFERENCES


A simple, accurate and precise spectrophotometric method has been developed for simultaneous estimation of escitalopram oxalate and clonazepam in combined dosage form. Simultaneous equation method is employed for simultaneous determination of escitalopram oxalate and clonazepam from combined dosage forms. In this method, the absorbance was measured at 238 nm for escitalopram oxalate and 273 nm for clonazepam. Linearity was observed in range of 5-100 µg/ml and 5-50 µg/ml for escitalopram and clonazepam respectively. Recovery studies confirmed the accuracy of proposed method and results were validated as per ICH guidelines. The method can be used for routine quality control of pharmaceutical formulation containing escitalopram and clonazepam.

Key words: Clonazepam, escitalopram, simultaneous estimation, UV spectrophotometry

A new fixed dose combination containing escitalopram oxalate (ESC) and clonazepam (CLO) is available in market in tablet dosage form. ESC[1] is an orally administered selective serotonin reuptake inhibitor. It is the pure S enantiomer of racemic bicyclic phthalane derivative of citalopram. Chemically it is S-(-) 1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5 phthalancarbonitrile oxalate. CLO is a benzodiazepine derivative similar to diazepam, with marked antiepileptic properties[2]. It is official in USP[3] and BP[4]. Chemically it is 5-(2-chlorophenyl)-1, 3-dihydro-7-nitro-2H-1,4-benzodiazepine-2-one. Nexito Plus is the commercial product that has been developed and marketed to treat the depression associated with anxiety.

Literature reports many analytical methods for quantitative determination of ESC and CLO individually in fixed dosage forms. These methods include estimation of ESC by LC-MS[5] and CLO by UV[6], HPLC[7-14] and gas chromatography[15]. However, no method is yet reported for simultaneous estimation of ESC oxalate and CLO in pharmaceutical preparation. Hence, the spectroscopic methods have been developed to estimate these two drugs from tablet dosage form.

The instrument used for the present study was UV/ Vis double beam spectrophotometer, (Model Shimadzu UV 2401PC) with 1 cm matched pair quartz cells. ESC oxalate and CLO were kindly supplied as a gift sample by Wockhardt Ltd., Aurangabad, India and NPIL, Pithampur, MP, India. All chemicals and reagents used were of AR grade and were purchased from Merck Chemicals, India.

Standard stock solution (1000 µg/ml) of ESC was prepared by dissolving 50 mg of ESC in 50 ml of methanol. Five milliliter of this stock solution was further diluted to 100 ml by 0.1N HCl to get final concentration of 50 µg/ml. CLO standard stock solution (100 µg/ml) was prepared by dissolving 5 mg of CLO in 50 ml of methanol. Five milliliter of this stock solution was further diluted to 100 ml by 0.1N HCl to get final concentration of 5 µg/ml. These diluted solutions were then scanned in the wavelength range of 200-400 nm (fig. 1). The overlain spectra of ESC and CLO showed the \( \lambda_{\text{max}} \) at 238 nm and 273 nm, respectively. Hence the two wavelengths were selected for estimation of ESC and CLO. For constructing calibration curves, two series of different concentration in the range of 1-200 µg/ml for ESC and 1-100 µg/ml for CLO were prepared in 0.1N HCl from stock solution. ESC and CLO obeyed linearity in the concentration range of 5-100 µg/ml and 5-50 µg/ml with correlation coefficient of 0.9996 and 0.9992, respectively. The absorptivities (E 1%, 1 cm) of both the drugs at two-selected wavelength were then determined. These calculated values were the mean of five independent determinations. Five binary mixture solutions of ESC and CLO (clinical dose ratio 5:0.5 mg of ESC and CLO) and the dilution of 5: 0.5 µg/ml were prepared. The quantitative estimation of these drugs were carried out by solving...
the simultaneous equations, \( C_x = \frac{(A_2 ay_1 - A_1 ay_2)}{(ax_2 ay_1 - ax_1 ay_2)} \) and \( Cy = \frac{(A_1 ax_2 - A_2 ax_1)}{(ax_2 ay_1 - ax_1 ay_2)} \), where, \( A_1 \) and \( A_2 \) are absorbance of diluted mixture at 238 and 273 nm, respectively, \( C_x \) and \( Cy \) are the concentration of ESC and CLO, respectively (g/100 ml), \( ax_1 \) (506.37) and \( ax_2 \) (58.98) are absorptivities of ESC at 238 and 273 nm, respectively, \( ay_1 \) (323.47) and \( ay_2 \) (621.47) are absorptivities of CLO at 238 and 273 nm, respectively.

For analysis of marketed formulations, twenty tablets were accurately weighed; average weight was calculated and finally powdered. An amount equivalent to one tablet (5 mg of ESC and 0.5 mg of CLO) was taken and transferred to 50.0 ml volumetric flask and sonicated with 5 ml methanol. About 10 ml of 0.1N HCl was added and shaken for 30 min. The volume was made up to the mark with 0.1N HCl and the solution was mixed and filtered through Whatman grade I filter paper. The final solution containing 50 μg/ml of ESC and 5 μg/ml of CLO was used as sample solution. The above solution was then analyzed for the content of ESC and CLO using the method described above. The results of the marketed formulation are given in the Table 1.

Degradation study of sample solutions were carried out by exposing an accurately weighed quantity of tablet powder equivalent to about 50 mg of ESC oxalate and 0.5 mg of CLO to various stress conditions for 24 h like at 50° after addition of 1.0 ml of 0.1N HCl, at 50° after addition of 1.0 ml of 0.1N NaOH, at 50° after addition of 1.0 ml of 3.0% H₂O₂, at 60° and in a UV-cabinet at 265 nm. The degradation study showed that CLO was completely degraded in basic as well as acidic condition. The specificity data are summarized in Table 2.

Determination of the limit of detection (LOD) and limit of quantitation (LOQ) is based on standard deviation of response and slope of calibration curve. LOD and LOQ of the methods were established according to ICH definitions- DL= 3.3σ/S, QL= 10σ/S, where DL- detection limit, QL- quantitation limit, σ-standard deviation of regression line, S-slope of the calibration curve. LOD at 238 nm was found to be 0.345, 1.01 and at 273 nm was 4.296, 1.09 for ESC and CLO, respectively. LOQ at 238 nm was found to be 1.045, 3.08 and at 273 nm was 13.01, 3.30 for ESC and CLO, respectively. System precision was determined by five replicate applications and five times measurement of laboratory mixture at the analytical concentration. This was performed by preparing laboratory mixtures of laboratory mixture at the ratio mentioned in marketed formulations. The results of the system precision were found to be 101.65±0.389 and 99.18±0.656 for ESC and CLO, respectively. System precision was determined by analyzing the marketed formulations. The results of method precision were found to be 99.07±0.619 and 98.56±0.597 for ESC and CLO, respectively. The % RSD for inter-day and intra-day precision was found to be 0.932, 1.255 for ESC and 0.470, 0.713 for CLO, respectively. The results of recovery studies performed by standard addition method being close to 100% are indicative of the accuracy of the method and shows that the method is free from interference of excipients present in the formulation. The results

| TABLE 1: RESULTS OF MARKETED FORMULATION, RECOVERY AND INTERMEDIATE PRECISION |
|---|---|---|---|---|
| **Drugs** | Parameters | % Labeled claim** | % Recovery* | Intermediate Precision** |
| | | | Interday | Intraday | Different analyst |
| ESC | Mean | 99.07 | 100.47 | 100.79 | 99.75 | 100.47 | 100.79 |
| | ±SD | 0.619 | 0.233 | 0.940 | 1.252 | 0.932 | 1.255 | 0.231 |
| | % RSD | 0.624 | 0.231 | 0.932 | 1.255 | 0.231 |
| CLO | Mean | 98.56 | 99.53 | 99.89 | 99.54 | 99.89 | 99.54 | 99.89 |
| | ±SD | 0.597 | 0.416 | 0.470 | 0.710 | 0.470 | 0.713 | 0.268 |
| | % RSD | 0.605 | 0.418 | 0.470 | 0.713 | 0.268 |

*Mean of nine determination, **Mean of five determination, SD is the standard deviation, RSD is the relative standard deviation

| TABLE 2: RESULTS OF SPECIFICITY DATA |
|---|---|---|---|---|
| **Drug** | Normal | Acid | Alkali | H₂O₂ | UV | Heat |
| ESC | 99.28 | 99.39 | 102.55 | 98.92 | 100.52 | 96.52 |
| CLO | 98.30 | 27.01 | 21.90 | 99.53 | 95.99 | 98.90 |
of recovery study are given in Table 1. Ruggedness of the method was observed by reproducibility of results under the conditions like different days and different analyst. The method was found to be specific, accurate and precise. Hence the method can be employed for routine quality control of pharmaceutical formulation containing ESC and CLO.

ACKNOWLEDGEMENTS

The authors thank the Head of Department, Department of Pharmaceutical Sciences, R.T.M. Nagpur University, Nagpur for providing laboratory facilities. Authors also wish to thank Wockhardt Ltd. and Nicholas Piramal India Ltd. for providing gift samples of escitalopram and clonazepam.

REFERENCES